Malignant Melanoma Stage IV Clinical Trial
Official title:
Randomized Controlled Phase II Clinical Trial on mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma Patients Who Are Disease-free Following the Local Treatment of Macrometastases.
This is an open label, 2-arm, 1-stage, randomized controlled phase II study in patients with AJCC stage IIIB/C & -IV melanoma. At baseline tumor assessment (using total body FDG-PET/CT), patients should be free from measurable tumor lesions (according to RECISTv1.1 definitions) following prior local therapy (e.g. following surgical resection, isolated limb perfusion, radiofrequency ablation, cryotherapy, radiotherapy, electrochemotherapy, …). Patients should not have symptomatic non-measurable tumor lesions (e.g. bone metastasis, or pleural effusion), and lesions treated by prior local therapy should be free from progression. Patients should not have received any prior systemic therapy (non-experimental or experimental).
This is an open label, 2-arm, 1-stage, randomized controlled phase II study in patients with
AJCC stage IIIB/C & -IV melanoma. At baseline tumor assessment (using total body
FDG-PET/CT), patients should be free from measurable tumor lesions (according to RECISTv1.1
definitions) following prior local therapy (e.g. following surgical resection, isolated limb
perfusion, radiofrequency ablation, cryotherapy, radiotherapy, electrochemotherapy, …).
Patients should not have symptomatic non-measurable tumor lesions (e.g. bone metastasis, or
pleural effusion), and lesions treated by prior local therapy should be free from
progression. Patients should not have received any prior systemic therapy (non-experimental
or experimental).
- Patients will be randomized between two treatment arms (Arm-A and -B). In study Arm-A,
patients will receive DC-administrations during one year following randomization.
Salvage treatment by local therapies will be allowed during the study treatment in
Arm-A. In study Arm-B, patients will initiate DC-administrations only after documented
recurrence of the melanoma that cannot be salvaged by local therapy.
- The primary endpoint of this clinical trial is to determine the rate (%) of patients
who are free from macrometastases (: measurable tumor lesions and symptomatic
non-measurable tumor lesions) at 1-year (= 52 weeks) after randomization.
Patients treated on Arm-B will serve as a contemporary control-arm to help interpreting the
outcome of patients treated in Arm-A. By design (phase II) this trial will not be powered to
statistically prove a predefined difference between the two study arms (this would require a
phase III design). Patients treated in Arm-B will be able to initiate immunotherapy with
autologous DC at the time of recurrence that can not be salvaged by local therapy.
Documentation of the anti-tumor activity and survival following DC-treatment at recurrence
in Arm-B patients will be a secondary objective of this clinical trial.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03132090 -
Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI
|
N/A | |
| Terminated |
NCT04577729 -
The IRMI-FMT Trial
|
N/A | |
| Completed |
NCT02439411 -
Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
|
||
| Completed |
NCT00313235 -
Combined Modality Treatment for Patients With Stage IV Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03166397 -
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05304546 -
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
|
Phase 2 | |
| Terminated |
NCT00722098 -
Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients
|
Phase 2 | |
| Terminated |
NCT03430947 -
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
|
Phase 2 | |
| Completed |
NCT01189383 -
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01983124 -
Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
|
Phase 2 | |
| Completed |
NCT01302496 -
Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
|
Phase 2 | |
| Not yet recruiting |
NCT03493230 -
Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )
|
N/A |